High-dose menaquinone-7 supplementation reduces cardiovascular calcification in a murine model of extraosseous calcification

Nutrients

Volumn 7, Issue 8, 2015, Pages 6991-7011

  Scheiber, Daniel ^a   Veulemans, Verena ^a   Horn, Patrick ^a   Chatrou, Martijn L ^b   Potthoff, Sebastian A ^a   Kelm, Malte ^a   Schurgers, Leon J ^b   Westenfeld, Ralf ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiovascular calcification; Chronic kidney disease; Matrix gla protein; Menaquinone 7; Vitamin K2

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CREATININE; FARNOQUINONE; MENAQUINONE; MENAQUINONE 7; MESSENGER RNA; OSTEOCALCIN; PHOSPHATE; TRANSCRIPTION FACTOR RUNX2; TRANSGELIN; UNCLASSIFIED DRUG; VITAMIN MK 7;

ABSORPTION SPECTROSCOPY; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE MONITORING; CALCIFICATION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELASTIC FIBER; EXTRAOSSEOUS CALCIFICATION; FEMALE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MINERALIZATION; NEPHRECTOMY; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; CHRONIC KIDNEY FAILURE; DIETARY SUPPLEMENT; DISEASE MODEL; DOSE RESPONSE; GENETICS; METABOLISM; VASCULAR CALCIFICATION; WISTAR RAT;

ANIMALS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; MALE; PHOSPHATES; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER; VASCULAR CALCIFICATION; VITAMIN K 2;

EID: 84940836409     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7085318     Document Type: Article

References (63)

1. Allison, M.A.; Criqui, M.H.; Wright, C.M. Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 331-336. [CrossRef] [PubMed]
2. Giachelli, C.M. The emerging role of phosphate in vascular calcification. Kidney Int. 2009, 75, 890-897. [CrossRef] [PubMed]
3. Schurgin, S.; Rich, S.; Mazzone, T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 2001, 24, 335-338. [CrossRef] [PubMed]
4. Vliegenthart, R.; Oudkerk, M.; Hofman, A.; Oei, H.H.; van Dijck, W.; van Rooij, F.J.; Witteman, J.C. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation 2005, 112, 572-577. [CrossRef] [PubMed]
5. Ketteler, M.; Schlieper, G.; Floege, J. Calcification and cardiovascular health-New insights into an old phenomenon. Hypertension 2006, 47, 1027-1034. [CrossRef] [PubMed]
6. Wu, M.; Rementer, C.; Giachelli, C.M. Vascular calcification: An update on mechanisms and challenges in treatment. Calcif. Tissue Int. 2013, 93, 365-373. [CrossRef] [PubMed]
7. Moe, S.M.; O'Neill, K.D.; Duan, D.; Ahmed, S.; Chen, N.X.; Leapman, S.B.; Fineberg, N.; Kopecky, K. Medial artery calcification in esrd patients is associated with deposition of bone matrix proteins. Kidney Int. 2002, 61, 638-647. [CrossRef] [PubMed]
8. Demer, L.L.; Tintut, Y. Vascular calcification: Pathobiology of a multifaceted disease. Circulation 2008, 117, 2938-2948. [CrossRef] [PubMed]
9. Chatrou, M.L.; Winckers, K.; Hackeng, T.M.; Reutelingsperger, C.P.; Schurgers, L.J. Vascular calcification: The price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012, 26, 155-166. [CrossRef] [PubMed]
10. Reaven, P.D.; Sacks, J. Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes. Diabetologia 2005, 48, 379-385. [CrossRef] [PubMed]
11. Okuno, S.; Ishimura, E.; Kitatani, K.; Fujino, Y.; Kohno, K.; Maeno, Y.; Maekawa, K.; Yamakawa, T.; Imanishi, Y.; Inaba, M.; et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis. Am. J. Kidney Dis. 2007, 49, 417-425. [CrossRef] [PubMed]
12. Schurgers, L.J.; Cranenburg, E.C.M.; Vermeer, C. Matrix gla-protein: The calcification inhibitor in need of vitamin k. Thromb. Haemost. 2008. [CrossRef]
13. Price, P.A.; Urist, M.R.; Otawara, Y. Matrix gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem. Biophys. Res. Commun. 1983, 117, 765-771. [CrossRef]
14. Luo, G.; Ducy, P.; McKee, M.D.; Pinero, G.J.; Loyer, E.; Behringer, R.R.; Karsenty, G. Spontaneous calcification of arteries and cartilage in mice lacking matrix gla protein. Nature 1997, 386, 78-81. [CrossRef] [PubMed]
15. Munroe, P.B.; Olgunturk, R.O.; Fryns, J.P.; van Maldergem, L.; Ziereisen, F.; Yuksel, B.; Gardiner, R.M.; Chung, E. Mutations in the gene encoding the human matrix gla protein cause keutel syndrome. Nat. Genet. 1999, 21, 142-144. [CrossRef] [PubMed]
16. Schurgers, L.J.; Uitto, J.; Reutelingsperger, C.P. Vitamin k-dependent carboxylation of matrix gla-protein: A crucial switch to control ectopic mineralization. Trends Mol. Med. 2013, 19, 217-226. [CrossRef] [PubMed]
17. Murshed, M.; Schinke, T.; McKee, M.D.; Karsenty, G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J. Cell Biol. 2004, 165, 625-630. [CrossRef] [PubMed]
18. Schurgers, L.J.; Teunissen, K.J.; Knapen, M.H.; Kwaijtaal, M.; van Diest, R.; Appels, A.; Reutelingsperger, C.P.; Cleutjens, J.P.; Vermeer, C. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (gla) protein: Undercarboxylated matrix gla protein as marker for vascular calcification. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1629-1633. [CrossRef] [PubMed]
19. Berkner, K.L.; Runge, K.W. The physiology of vitamin k nutriture and vitamin k-dependent protein function in atherosclerosis. J. Thromb. Haemost. 2004, 2, 2118-2132. [CrossRef] [PubMed]
20. Rennenberg, R.J.M.W.; van Varik, B.J.; Schurgers, L.J.; Hamulyak, K.; ten Cate, H.; Leiner, T.; Vermeer, C.; de Leeuw, P.W.; Kroon, A.A. Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010, 115, 5121-5123. [CrossRef] [PubMed]
21. Pilkey, R.M.; Morton, A.R.; Boffa, M.B.; Noordhof, C.; Day, A.G.; Su, Y.H.; Miller, L.M.; Koschinsky, M.L.; Booth, S.L. Subclinical vitamin k deficiency in hemodialysis patients. Am. J. Kidney Dis. 2007, 49, 432-439. [CrossRef] [PubMed]
22. Schurgers, L.J.; Barreto, D.V.; Barreto, F.C.; Liabeuf, S.; Renard, C.; Magdeleyns, E.J.; Vermeer, C.; Choukroun, G.; Massy, Z.A. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. Clin. J. Am. Soc. Nephrol. 2010, 5, 568-575. [CrossRef] [PubMed]
23. Shea, M.K.; O'Donnell, C.J.; Vermeer, C.; Magdeleyns, E.J.P.; Crosier, M.D.; Gundberg, C.M.; Ordovas, J.M.; Kritchevsky, S.B.; Booth, S.L. Circulating uncarboxylated matrix gla protein is associated with vitamin k nutritional status, but not coronary artery calcium, in older adults. J. Nutr. 2011, 141, 1529-1534. [CrossRef] [PubMed]
24. Ueland, T.; Gullestad, L.; Dahl, C.P.; Aukrust, P.; Aakhus, S.; Solberg, O.G.; Vermeer, C.; Schurgers, L.J. Undercarboxylated matrix gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J. Intern. Med. 2010, 268, 483-492. [CrossRef] [PubMed]
25. Ueland, T.; Dahl, C.P.; Gullestad, L.; Aakhus, S.; Broch, K.; Skardal, R.; Vermeer, C.; Aukrust, P.; Schurgers, L.J. Circulating levels of non-phosphorylated undercarboxylated matrix gla protein are associated with disease severity in patients with chronic heart failure. Clin. Sci. 2011, 121, 119-127. [CrossRef] [PubMed]
26. Cranenburg, E.C.; Koos, R.; Schurgers, L.J.; Magdeleyns, E.J.; Schoonbrood, T.H.; Landewe, R.B.; Brandenburg, V.M.; Bekers, O.; Vermeer, C. Characterisation and potential diagnostic value of circulating matrix gla protein (mgp) species. Thromb. Haemost. 2010, 104, 811-822. [PubMed]
27. Westenfeld, R.; Krueger, T.; Schlieper, G.; Cranenburg, E.C.; Magdeleyns, E.J.; Heidenreich, S.; Holzmann, S.; Vermeer, C.; Jahnen-Dechent, W.; Ketteler, M.; et al. Effect of vitamin k2 supplementation on functional vitamin k deficiency in hemodialysis patients: A randomized trial. Am. J. Kidney Dis. 2012, 59, 186-195. [CrossRef] [PubMed]
28. Gonnet, M.; Lethuaut, L.; Boury, F. New trends in encapsulation of liposoluble vitamins. J. Control. Release 2010, 146, 276-290. [CrossRef] [PubMed]
29. Gijsbers, B.L.; Jie, K.S.; Vermeer, C. Effect of food composition on vitamin k absorption in human volunteers. Br. J. Nutr. 1996, 76, 223-229. [CrossRef] [PubMed]
30. Schurgers, L.J.; Vermeer, C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin k concentrations. Haemostasis 2000, 30, 298-307. [PubMed]
31. Beulens, J.W.J.; Bots, M.L.; Atsma, F.; Bartelink, M.L.E.L.; Prokop, M.; Geleijnse, J.M.; Witteman, J.C.M.; Grobbee, D.E.; van der Schouw, Y.T. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009, 203, 489-493. [CrossRef] [PubMed]
32. Geleijnse, J.M.; Vermeer, C.; Grobbee, D.E.; Schurgers, L.J.; Knapen, M.H.; van der Meer, I.M.; Hofman, A.; Witteman, J.C. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The rotterdam study. J. Nutr. 2004, 134, 3100-3105. [PubMed]
33. Kruger, T.; Oelenberg, S.; Kaesler, N.; Schurgers, L.J.; van de Sandt, A.M.; Boor, P.; Schlieper, G.; Brandenburg, V.M.; Fekete, B.C.; Veulemans, V.; et al. Warfarin induces cardiovascular damage in mice. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2618-2624. [CrossRef] [PubMed]
34. Schurgers, L.J.; Spronk, H.M.; Soute, B.A.; Schiffers, P.M.; DeMey, J.G.; Vermeer, C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin k in rats. Blood 2007, 109, 2823-2831. [CrossRef] [PubMed]
35. Spronk, H.M.; Soute, B.A.; Schurgers, L.J.; Thijssen, H.H.; de Mey, J.G.; Vermeer, C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J. Vasc. Res. 2003, 40, 531-537. [CrossRef] [PubMed]
36. Perez-Ruiz, L.; Ros-Lopez, S.; Cardus, A.; Fernandez, E.; Valdivielso, J.M. A forgotten method to induce experimental chronic renal failure in the rat by ligation of the renal parenchyma. Nephron. Exp. Nephrol. 2006, 103, e126-e130. [CrossRef] [PubMed]
37. Ng, K.; Hildreth, C.M.; Phillips, J.K.; Avolio, A.P. Aortic stiffness is associated with vascular calcification and remodeling in a chronic kidney disease rat model. Am. J. Physiol. Renal Physiol. 2011, 300, F1431-F1436. [CrossRef] [PubMed]
38. Shobeiri, N.; Adams, M.A.; Holden, R.M. Vascular calcification in animal models of ckd: A review. Am. J. Nephrol. 2010, 31, 471-481. [CrossRef] [PubMed]
39. Fleck, C.; Appenroth, D.; Jonas, P.; Koch, M.; Kundt, G.; Nizze, H.; Stein, G. Suitability of 5/6 nephrectomy (5/6nx) for the induction of interstitial renal fibrosis in rats-Influence of sex, strain, and surgical procedure. Exp. Toxicol. Pathol. 2006, 57, 195-205. [CrossRef] [PubMed]
40. El-Achkar, T.M.; Ohmit, S.E.; McCullough, P.A.; Crook, E.D.; Brown, W.W.; Grimm, R.; Bakris, G.L.; Keane, W.F.; Flack, J.M. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The kidney early evaluation program. Kidney Int. 2005, 67, 1483-1488. [CrossRef] [PubMed]
41. Shioi, A.; Katagi, M.; Okuno, Y.; Mori, K.; Jono, S.; Koyama, H.; Nishizawa, Y. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: Roles of tumor necrosis factor-alpha and oncostatin m derived from macrophages. Circ. Res. 2002, 91, 9-16. [CrossRef]
42. Kendrick, J.; Chonchol, M. The role of phosphorus in the development and progression of vascular calcification. Am. J. Kidney Dis. 2011, 58, 826-834. [CrossRef] [PubMed]
43. El-Abbadi, M.M.; Pai, A.S.; Leaf, E.M.; Yang, H.Y.; Bartley, B.A.; Quan, K.K.; Ingalls, C.M.; Liao, H.W.; Giachelli, C.M. Phosphate feeding induces arterial medial calcification in uremic mice: Role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009, 75, 1297-1307. [CrossRef] [PubMed]
44. Steitz, S.A.; Speer, M.Y.; Curinga, G.; Yang, H.Y.; Haynes, P.; Aebersold, R.; Schinke, T.; Karsenty, G.; Giachelli, C.M. Smooth muscle cell phenotypic transition associated with calcification: Upregulation of cbfa1 and downregulation of smooth muscle lineage markers. Circ. Res. 2001, 89, 1147-1154. [CrossRef] [PubMed]
45. Hakuno, D.; Kimura, N.; Yoshioka, M.; Mukai, M.; Kimura, T.; Okada, Y.; Yozu, R.; Shukunami, C.; Hiraki, Y.; Kudo, A.; et al. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and mmp production in humans and rodents. J. Clin. Invest. 2010, 120, 2292-2306. [CrossRef] [PubMed]
46. Hixson, J.E.; Shimmin, L.C.; Montasser, M.E.; Kim, D.K.; Zhong, Y.; Ibarguen, H.; Follis, J.; Malcom, G.; Strong, J.; Howard, T.; et al. Common variants in the periostin gene influence development of atherosclerosis in young persons. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1661-1667. [CrossRef] [PubMed]
47. Sen, K.; Lindenmeyer, M.T.; Gaspert, A.; Eichinger, F.; Neusser, M.A.; Kretzler, M.; Segerer, S.; Cohen, C.D. Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am. J. Pathol. 2011, 179, 1756-1767. [CrossRef] [PubMed]
48. Bostrom, K.; Watson, K.E.; Horn, S.; Wortham, C.; Herman, I.M.; Demer, L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J. Clin. Invest. 1993, 91, 1800-1809. [CrossRef] [PubMed]
49. Ciceri, P.; Elli, F.; Brenna, I.; Volpi, E.; Romagnoli, S.; Tosi, D.; Braidotti, P.; Brancaccio, D.; Cozzolino, M. Lanthanum prevents high phosphate-induced vascular calcification by preserving vascular smooth muscle lineage markers. Calcif. Tissue Int. 2013, 92, 521-530. [CrossRef] [PubMed]
50. Kaesler, N.; Magdeleyns, E.; Herfs, M.; Schettgen, T.; Brandenburg, V.; Fliser, D.; Vermeer, C.; Floege, J.; Schlieper, G.; Kruger, T. Impaired vitamin k recycling in uremia is rescued by vitamin k supplementation. Kidney Int. 2014, 86, 286-293. [CrossRef] [PubMed]
51. Tabb, M.M.; Sun, A.; Zhou, C.; Grun, F.; Errandi, J.; Romero, K.; Pham, H.; Inoue, S.; Mallick, S.; Lin, M.; et al. Vitamin k2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor sxr. J. Biol. Chem. 2003, 278, 43919-43927. [CrossRef] [PubMed]
52. Viegas, C.S.; Rafael, M.S.; Enriquez, J.L.; Teixeira, A.; Vitorino, R.; Luis, I.M.; Costa, R.M.; Santos, S.; Cavaco, S.; Neves, J.; et al. Gla-rich protein acts as a calcification inhibitor in the human cardiovascular system. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 399-408. [CrossRef]
53. Tsuchiya, N.; Matsushima, S.; Takasu, N.; Kyokawa, Y.; Torii, M. Glomerular calcification induced by bolus injection with dibasic sodium phosphate solution in sprague-dawley rats. Toxicol. Pathol. 2004, 32, 408-412. [CrossRef] [PubMed]
54. Eknoyan, G.; Levin, N.W. K/doqi clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39, S14-S266.
55. McCarty, M.F.; DiNicolantonio, J.J. Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with plant-based diets, phosphate binders, niacin, and avoidance of phosphate additives. Nutrition 2014, 30, 739-747. [CrossRef] [PubMed]
56. Pucaj, K.; Rasmussen, H.; Moller, M.; Preston, T. Safety and toxicological evaluation of a synthetic vitamin k2, menaquinone-7. Toxicol. Mech. Methods 2011, 21, 520-532. [CrossRef] [PubMed]
57. Holden, R.M.; Morton, A.R.; Garland, J.S.; Pavlov, A.; Day, A.G.; Booth, S.L. Vitamins k and d status in stages 3-5 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010, 5, 590-597. [CrossRef] [PubMed]
58. Fusaro, M.; Noale, M.; Viola, V.; Galli, F.; Tripepi, G.; Vajente, N.; Plebani, M.; Zaninotto, M.; Guglielmi, G.; Miotto, D.; et al. Vitamin k, vertebral fractures, vascular calcifications, and mortality: Vitamin k italian (viki) dialysis study. J. Bone Miner. Res. 2012, 27, 2271-2278. [CrossRef] [PubMed]
59. Brandenburg, V.M.; Schurgers, L.J.; Kaesler, N.; Pusche, K.; van Gorp, R.H.; Leftheriotis, G.; Reinartz, S.; Koos, R.; Kruger, T. Prevention of vasculopathy by vitamin k supplementation: Can we turn fiction into fact? Atherosclerosis 2015, 240, 10-16. [CrossRef] [PubMed]
60. Taddei, S.; Nami, R.; Bruno, R.M.; Quatrini, I.; Nuti, R. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail. Rev. 2011, 16, 615-620. [CrossRef] [PubMed]
61. Feihl, F.; Liaudet, L.; Levy, B.I.; Waeber, B. Hypertension and microvascular remodelling. Cardiovasc. Res. 2008, 78, 274-285. [CrossRef] [PubMed]
62. Li, S.;Wang, X.; Li, Y.; Kost, C.K., Jr.; Martin, D.S. Bortezomib, a proteasome inhibitor, attenuates angiotensin ii-induced hypertension and aortic remodeling in rats. PLoS One 2013, 8, e78564. [CrossRef] [PubMed]
63. Ro, A.; Kageyama, N. Pathomorphometry of ruptured intracranial vertebral arterial dissection: Adventitial rupture, dilated lesion, intimal tear, and medial defect. J. Neurosurg. 2013, 119, 221-227. [CrossRef] [PubMed]